Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

On World Health Day,a 31 country Ipsos Health Service Report 2024 showsthe health concernsbothering Indians most were ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of breaking into a market ...

The growing number of Australians with obesity is causing economic damage but should the taxpayer fund weight-loss drugs?

Find insight on Fisher & Paykel Healthcare, Hims & Hers, GSK and more in the latest Market Talks covering health care.

Midnight is approaching in LA, and outside the Palomino Club in North Hollywood, the members of Canned Heat and their entourage are kicking back in the yard. It’s April 4, 1981. The band have just ...

While pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking ...

Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the ...